Read More Pharma Industry News Savara’s $130m stock offering strengthens cash position ahead of MOLBREEVI launch Savara raises $130 million through stock and warrant sale to fund MOLBREEVI’s rare-disease launch—find out how this deal reshapes its commercialization path. bySoujanya RaviOctober 30, 2025